Skip to main content
SpringerLink
Log in

Imaging in Gene Therapy of Patients with Glioma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Over 10 years ago, the first successful gene therapy paradigms for experimental brain tumors models have been conducted, and they were thought to revolutionize the treatment of patients with gliomas. Application of gene therapy has been quickly forced into clinical trials, the first patients being enrolled in 1994, with overall results being disappointing. However, single patients seemed to benefit from gene therapy showing long-term treatment response, and most of these patients bearing small glioblastomas. Whereas the gene therapy itself has been performed with high sophistication, limited attention has been paid on technologies, which (i) allow an identification of viable target tissue in heterogenous glioma tissue and which (ii) enable an assessment of successful vector administration and vector-mediated gene expression in vivo. However, these measures are a prerequisite for the development of successful gene therapy in the clinical application. As biological treatment strategies such as gene and cell-based therapies hold promise to selectively correct disease pathogenesis, successful clinical implementation of these treatment strategies rely on the establishment of molecular imaging technology allowing the non-invasive assessment of endogenous and exogenous gene expression in vivo. Imaging endogenous gene expression will allow the characterization and identification of target tissue for gene therapy. Imaging exogenously introduced cells and genes will allow the determination of the `tissue dose' of transduced cell function and vector-mediated gene expression, which in turn can be correlated to the induced therapeutic effect. Only these combined strategies of non-invasive imaging of gene expression in vivo will enable the establishment of safe and efficient vector administration and gene therapy protocols for clinical application. Here, we review some aspects of imaging in gene therapy trials for glioblastoma, and we present a `proof-of-principle' 2nd-generation gene therapy protocol integrating molecular imaging technology for the establishment of efficient gene therapy in clinical application.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/CYP2B1 and ganciclovir/HSV-TK gene therapies. Cancer Res 59: 3861-3865, 1999

    Google Scholar 

  2. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 11: 67-76, 2000

    Google Scholar 

  3. Toda M, Martuza RL, Kojima H, Rabkin SD: In situ cancer vaccination: an IL-12 defective vector/replicationcompetent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160: 4457-4464, 1998

    Google Scholar 

  4. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 20; 10: 2741-2755, 1999

    Google Scholar 

  5. Jacobs A, Fraefel C, Breakefield XO: HSV-1 based vectors for gene therapy of neurological diseases and brain tumors: Part I: HSV-1 structure, replication and pathogenesis. Neoplasia 1: 387-401, 1999

    Google Scholar 

  6. Jacobs A, Fraefel C, Breakefield XO: HSV-1 based vectors for gene therapy of neurological diseases and brain tumors: Part II: Vector systems and applications. Neoplasia 1: 402-416, 1999

    Google Scholar 

  7. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992

    Google Scholar 

  8. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 3: 608-614, 1991

    Google Scholar 

  9. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J: A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 20; 9: 2595-2604, 1998

    Google Scholar 

  10. Rainov NG: Aphase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 20; 11: 2389-2401, 2000

    Google Scholar 

  11. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3: 1354-1361, 1997

    Google Scholar 

  12. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 10: 2325-2335, 1999

    Google Scholar 

  13. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867-874, 2000

    Google Scholar 

  14. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859-866, 2000

    Google Scholar 

  15. Voges J, Weber F, Reszka R, Sturm V, Jacobs A, Heiss WD, Wiestler O, Kapp JF: Clinical protocol. Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme. Hum Gene Ther 13: 675-685, 2002

    Google Scholar 

  16. Harsh GR, Deisboeck TS, Louis DN, Hilton J, Colvin M, Silver JS, Qureshi NH, Kracher J, Finkelstein D, Chiocca EA, Hochberg FH: Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 92: 804-811, 2000

    Google Scholar 

  17. Palu G, Cavaggioni A, Calvi P, Franchin E, Pizzato M, Boschetto R, Parolin C, Chilosi M, Ferrini S, Zanusso A, Colombo F: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther 6: 330-337, 1999

    Google Scholar 

  18. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, Harland J, Mabbs R, Brown M: The potential for efficacy of the modified (ICP 34.5(?)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398-406, 2002

    Google Scholar 

  19. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C, Wagner R, Wienhard K, Heiss WD: Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358: 727-729, 2001

    Google Scholar 

  20. Tjuvajev JG, Stockhammer G, Desai R, Uehara H, Watanabe K, Gansbacher B, Blasberg RG: Imaging the expression of transfected genes in vivo. Cancer Res 55: 6126–6132, 1995

    Google Scholar 

  21. Hollon T: Researchers and regulators reflect on first gene therapy death. Nat Med 6: 6, 2000

    Google Scholar 

  22. Blasberg RG, Tjuvajev JG: Molecular-Genetic Imaging: A nuclear medicine-based perspective. Mol Imaging 1: 280-300, 2002

    Google Scholar 

  23. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2: 683-693, 2002

    Google Scholar 

  24. Jacobs AH, Dittmar C, Winkeler A, Garlip G, Heiss WD: Molecular imaging of gliomas. Molecular Imaging 1: 309-335, 2002

    Google Scholar 

  25. Shimizu K, Miyao Y, Tamura M, Kishima H, Ohkawa M, Mabuchi E, Yamada M, Hayakawa T, Ikenaka K: Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma. Jpn J Cancer Res 86: 1010-1013, 1995

    Google Scholar 

  26. Izquierdo M, Martin V, de Felipe P, Izquierdo JM, Perez-Higueras A, Cortes ML, Paz JF, Isla A, Blazquez MG: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 3: 491-495, 1996

    Google Scholar 

  27. Deliganis AV, Baxter AB, Berger MS, Marcus SG, Maravilla KR: Serial MR in gene therapy for recurrent glioblastoma: initial experience andwork in progress. AJNR Am J Neuroradiol 18: 1401-1406, 1997

    Google Scholar 

  28. Floeth FW, Aulich A, Langen KJ, Burger KJ, Bock WJ, Weber F: MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. AJNR Am J Neuroradiol 22: 1517-1527, 2001

    Google Scholar 

  29. Smith MM, Thompson JE, Castillo M, Cush S, Mukherji SK, Miller CH, Quattrocchi KB: MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol 17: 1065-1071, 1996

    Google Scholar 

  30. Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D: Longterm survival after gene therapy for a recurrent glioblastoma. Neurology 58: 1109-1112, 2002

    Google Scholar 

  31. Adachi N, Konu DL, Frei K, Yonekawa Y: [The HSVTK/ GCV gene therapy in five cases of recurrent glioblastoma multiforme]. No Shinkei Geka 28: 865-871, 2000

    Google Scholar 

  32. Stockhammer G, Brotchi J, Leblanc R, Bernstein M, Schackert G, Weber F, Ostertag C, Mulder NH, Mellstedt H, Seiler R, Yonekawa Y, Twerdy K, Kostron H, De Witte O, Lambermont M, Velu T, Laneuville P, Villemure JG, Rutka JT, Warnke P, Laseur M, Mooij JJ, Boethius J, Mariani L, Gianella-Borradori A: Gene therapy for glioblastoma multiforme: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. J Mol Med 75: 300-304, 1997

    Google Scholar 

  33. Kuwert T, Probst-Cousin S, Woesler B, Morgenroth C, Lerch H, Matheja P, Palkovic S, Schafers M, Wassmann H, Gullotta F, Schober O: Iodine-123-alpha-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity. J Nucl Med 38: 1551-1555, 1997

    Google Scholar 

  34. Langen KJ, Ziemons K, Kiwit JC, Herzog H, Kuwert T, Bock WJ, Stocklin G, Feinendegen LE, Muller-Gartner HW: 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 38: 517-522, 1997

    Google Scholar 

  35. Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M: Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 38: 802-808, 1997

    Google Scholar 

  36. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, Johansson R, Vapalahti M, Yla-Herttuala S: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11: 2197-2205, 2000

    Google Scholar 

  37. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1: 195-203, 2000

    Google Scholar 

  38. Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, Mollman J, Phillips PC, Wheeldon EB, Wilson JM: Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 7: 1465-1482, 1996

    Google Scholar 

  39. Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D, Cross P, Hughes J, Gao G, Wilson JM, Propert K: Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 12: 97-113, 2001

    Google Scholar 

  40. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 73: 6319-6326, 1999

    Google Scholar 

  41. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 72: 631-639, 1991

    Google Scholar 

  42. Brown SM, MacLean AR, McKie EA, Harland J: The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34. J Virol 71: 9442-9449, 1997

    Google Scholar 

  43. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938-943, 1995

    Google Scholar 

  44. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM, Trojanowski JQ, Fraser NW: Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 73: 636-648, 1995

    Google Scholar 

  45. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, MacLean A, Fraser NW: Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211: 94-101, 1995

    Google Scholar 

  46. Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG: Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 61: 2983-2995, 2001

    Google Scholar 

  47. Bradbury J: Oncolytic viral anti-cancer therapy: a magic bullet? Lancet 357: 614, 2001

    Google Scholar 

  48. MacKie RM, Stewart B, Brown SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357: 525-526, 2001

    Google Scholar 

  49. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, Phelps ME, Larson SM, Balatoni J, Finn R, Sadelain M, Tjuvajev J, Blasberg R: Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2: 118-138, 2000

    Google Scholar 

  50. Tjuvajev JG, Chen SH, Joshi A, Joshi R, Guo ZS, Balatoni J, Ballon D, Koutcher J, Finn R, Woo SL, Blasberg RG: Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 59: 5186-5193, 1999

    Google Scholar 

  51. Herholz K, Wienhard K, Heiss WD: Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2: 240-265, 1990

    Google Scholar 

  52. Price P: PET as a potential tool for imaging molecular mechanisms of oncology in man. Trends Mol Med 7: 442-446, 2001

    Google Scholar 

  53. Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J, Beattie B, Koutcher J, Larson S, Blasberg RG: Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 56: 4087-4095, 1996

    Google Scholar 

  54. de Vries E, Vaalburg W: Positron emission tomography: measurement of transgene expression. Methods 27: 234, 2002

    Google Scholar 

  55. Wiebe LI, Knaus EE: Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression. Curr Pharm Des 7: 1893–1906, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Max Planck-Institute for Neurological Research, Center of Molecular Medicine (ZMMK), Germany

    A.H. Jacobs, J. Voges, L.W. Kracht, C. Dittmar, A. Winkeler, A. Thomas, K. Wienhard, K. Herholz & W.D. Heiss

  2. University of Cologne, Cologne, Germany

    A.H. Jacobs, J. Voges, L.W. Kracht, C. Dittmar, A. Winkeler, A. Thomas, K. Wienhard, K. Herholz & W.D. Heiss

Authors
  1. A.H. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Voges
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L.W. Kracht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Dittmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Winkeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Wienhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Herholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W.D. Heiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobs, A., Voges, J., Kracht, L. et al. Imaging in Gene Therapy of Patients with Glioma. J Neurooncol 65, 291–305 (2003). https://doi.org/10.1023/B:NEON.0000003658.51816.3f

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:NEON.0000003658.51816.3f

Search

Navigation